Logo image of SPPI

SPECTRUM PHARMACEUTICALS INC (SPPI) Stock Fundamental Analysis

NASDAQ:SPPI - Nasdaq - US84763A1088 - Common Stock - Currency: USD

1.03  0 (0%)

After market: 1.04 +0.01 (+0.97%)

Fundamental Rating

2

Overall SPPI gets a fundamental rating of 2 out of 10. We evaluated SPPI against 571 industry peers in the Biotechnology industry. SPPI may be in some trouble as it scores bad on both profitability and health. SPPI has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SPPI has reported negative net income.
In the past year SPPI has reported a negative cash flow from operations.
SPPI had negative earnings in each of the past 5 years.
In the past 5 years SPPI always reported negative operating cash flow.
SPPI Yearly Net Income VS EBIT VS OCF VS FCFSPPI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -50M -100M -150M

1.2 Ratios

SPPI has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SPPI Yearly ROA, ROE, ROICSPPI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -100 -200 -300

1.3 Margins

With a decent Gross Margin value of 32.34%, SPPI is doing good in the industry, outperforming 75.42% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for SPPI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 32.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPPI Yearly Profit, Operating, Gross MarginsSPPI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -200 -400 -600

More info and screens

2

2. Health

2.1 Basic Checks

SPPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SPPI has been increased compared to 1 year ago.
The debt/assets ratio for SPPI is higher compared to a year ago.
SPPI Yearly Shares OutstandingSPPI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M
SPPI Yearly Total Debt VS Total AssetsSPPI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -14.02, we must say that SPPI is in the distress zone and has some risk of bankruptcy.
SPPI has a Altman-Z score of -14.02. This is amonst the worse of the industry: SPPI underperforms 86.78% of its industry peers.
A Debt/Equity ratio of 1.08 is on the high side and indicates that SPPI has dependencies on debt financing.
SPPI has a Debt to Equity ratio of 1.08. This is amonst the worse of the industry: SPPI underperforms 83.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.08
Debt/FCF N/A
Altman-Z -14.02
ROIC/WACCN/A
WACC8.97%
SPPI Yearly LT Debt VS Equity VS FCFSPPI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 2.71 indicates that SPPI has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.71, SPPI is doing worse than 76.44% of the companies in the same industry.
A Quick Ratio of 2.38 indicates that SPPI has no problem at all paying its short term obligations.
With a Quick ratio value of 2.38, SPPI is not doing good in the industry: 77.80% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.71
Quick Ratio 2.38
SPPI Yearly Current Assets VS Current LiabilitesSPPI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.62% over the past year.
EPS 1Y (TTM)58.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SPPI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.88% yearly.
The Revenue is expected to grow by 98.74% on average over the next years. This is a very strong growth
EPS Next Y88.67%
EPS Next 2Y51.91%
EPS Next 3Y39.88%
EPS Next 5YN/A
Revenue Next Year722.64%
Revenue Next 2Y275.85%
Revenue Next 3Y179.1%
Revenue Next 5Y98.74%

3.3 Evolution

SPPI Yearly Revenue VS EstimatesSPPI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
SPPI Yearly EPS VS EstimatesSPPI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SPPI. In the last year negative earnings were reported.
SPPI is valuated cheaply with a Price/Forward Earnings ratio of 7.97.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SPPI indicates a rather cheap valuation: SPPI is cheaper than 98.98% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of SPPI to the average of the S&P500 Index (22.70), we can say SPPI is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 7.97
SPPI Price Earnings VS Forward Price EarningsSPPI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPPI Per share dataSPPI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SPPI's earnings are expected to grow with 39.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.91%
EPS Next 3Y39.88%

More info and screens

0

5. Dividend

5.1 Amount

SPPI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SPECTRUM PHARMACEUTICALS INC

NASDAQ:SPPI (7/31/2023, 8:00:02 PM)

After market: 1.04 +0.01 (+0.97%)

1.03

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-10 2023-08-10/bmo
Earnings (Next)11-08 2023-11-08/bmo
Inst Owners0.06%
Inst Owner Change0%
Ins Owners1.22%
Ins Owner Change0%
Market Cap211.40M
Analysts50
Price Target1.29 (25.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.99%
Min EPS beat(2)54.61%
Max EPS beat(2)69.36%
EPS beat(4)3
Avg EPS beat(4)34.68%
Min EPS beat(4)-5.49%
Max EPS beat(4)69.36%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)25.37%
Min Revenue beat(2)11.17%
Max Revenue beat(2)39.57%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-34.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)44.45%
EPS NY rev (1m)78.12%
EPS NY rev (3m)78.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)40.01%
Revenue NY rev (1m)47.89%
Revenue NY rev (3m)47.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.97
P/S 8.22
P/FCF N/A
P/OCF N/A
P/B 7.89
P/tB 7.89
EV/EBITDA N/A
EPS(TTM)-0.36
EYN/A
EPS(NY)0.13
Fwd EY12.54%
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.13
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 32.34%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 1.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 155.46%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.71
Quick Ratio 2.38
Altman-Z -14.02
F-Score3
WACC8.97%
ROIC/WACCN/A
Cap/Depr(3y)772.71%
Cap/Depr(5y)966.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y88.67%
EPS Next 2Y51.91%
EPS Next 3Y39.88%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year722.64%
Revenue Next 2Y275.85%
Revenue Next 3Y179.1%
Revenue Next 5Y98.74%
EBIT growth 1Y50.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.22%
OCF growth 3YN/A
OCF growth 5YN/A